
High Dose of Tisagenlecleucel Linked to Better Survival Rate for B-Cell Acute Lymphoblastic Leukemia
For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel increased their rate of survival after 1 year by nearly 30%.





























